Browsing by Author "Dogan, O"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Evaluation of blast-induced ground vibration effects in a new residential zone
    Dogan, O; Anil, Ö; Akbas, SO; Kantar, E; Erdem, RT
    The results from an experimental blasting program that was performed at the special explosives training field of the General Directorate of Security in Ankara, where new residential blocks are planned to be constructed nearby, are presented. With the objective of estimating the blast-induced ground vibration effects on the proposed structures, various blasting parameters of nineteen surface and underground explosions were recorded in two directions at three measurement stations. Site-specific empirical relationships between peak particle velocity, the amount of explosive and the distance were developed. These relationships were used to construct a practical blasting chart, which gives the maximum amount of explosive to be used as a function of distance, for future underground and surface blasting operations in the training field. Since the use of peak particle velocity in the field of civil engineering has been limited so far, site-specific parameters were also estimated to predict the blast-induced horizontal peak ground acceleration. Then, an attempt was made to investigate the dynamic responses of four and six storey reinforced concrete structures that consist of frame and shear wall type structural systems under the measured accelerations using finite element analysis. The limitations of this approach were discussed within the context of damage estimation. (C) 2013 Elsevier Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Mitogenome evolution in Trichoderma afroharzianum strains: for a better understanding of distinguishing genus
    Özkale, E; Dogan, O; Budak, M; Korkmaz, EM
    Trichoderma afroharzianum (Hypocreales) is known as an important mycoparasite and biocontrol fungus and feeds on fungal material by parasitizing other fungi. Recent studies indicate that this species is also an ear rot pathogen in Europe. Here, the complete mitochondrial genome of three T. afroharzianum strains was sequenced using next-generation sequencing and comparatively characterized by the reported Trichoderma mitogenomes. T. afroharzianum mitogenomes were varying between 29 511 bp and 29 517 bp in length, with an average A + T content of 72.32%. These mitogenomes contain 14 core protein coding genes (PCGs), 22 tRNAs, two rRNAs, one gene encoding the ribosomal protein S3, and three or four genes including conserved domains for the homing endonucleases (HEGs; GIY-YIG type and LAGLIDADG type). All PCGs are initiated by ATG codons, except for atp8, and all are terminated with TAA. A significant correlation was observed between nucleotide composition and codon preference. Four introns belonging to the group I intron class were predicted, accounting for about 14.54% of the size of the mitogenomes. Phylogenetic analyses confirmed the positions of T. afroharzianum strains within the genus of Trichoderma and supported a sister group relationship between T. afroharzianum and T. simmonsii. The recovered trees also supported the monophyly of all included families and of the genus of Acremonium. The characterization of mitochondrial genome of T. afroharzianum contributes to the understanding of phylogeny and evolution of Hypocreales.
  • No Thumbnail Available
    Item
    Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study
    Kahraman, S; Hizal, M; Demirel, BC; Guven, DC; Gumusay, O; Uluc, BO; Bayram, E; Gulbagci, B; Yasar, A; Davarci, SE; Mocan, EE; Acar, O; Isik, D; Aydin, E; Karakas, Y; Ozcelik, M; Keser, M; Okutur, SK; Eren, O; Menekse, S; Aydin, D; Yilmaz, F; Dogan, O; Ozkanli, G; Yucel, H; Sunar, V; Aykan, MB; Ozdemir, O; Duman, BB; Keskinkilic, M; Sakalar, T; Inal, A; Karaoglanoglu, M; Aksoy, A; Er, MM; Turhal, NS; Kalkan, NO; Sendur, MAN
    Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy is more effective than ET alone and is safe in elderly patients as well as young patients. Nevertheless, elderly and very old patients with HR+/HER2-MBC treated with CDK4/6 inhibitor (CDK4/6i) combinations are relatively underrepresented in randomized controlled trials. To contribute to the literature, we investigated the real-world efficacy, factors associated with survival and the rates of adverse events (AEs) of the treatment with palbociclib or ribociclib plus ET in the HR+/HER2- MBC patient cohort over the age of 65 for age subgroups. In this retrospective study, 348 patients were divided into subgroups: 65-69 years old, 70-79 years old and 80 years and older. Median PFS (mPFS) for whole group was 18.3 (95% CI,14.3-22.3) months. There was no significant difference in mPFS between age groups (p = 0.75). The estimated median OS (mOS) was 39.5 (95% CI, 24.9-54.1) months and there was no significant difference between age groups (p = 0.15). There was a meaningfull numerical difference that did not reach statistical significance in patients who received CDK4/6i treatment as the first line for MBC. Grade 3-4 AEs were reported in 42.7% for the entire group, and neutropenia was the most common (37.3%). It can be concluded that combination therapy with palbociclib or ribociclib with an ET partner has similar efficacy and is safe among subgroups of older patients diagnosed with HR+/HER2-MBC.